Epoxide hydrolase 3, encoded by the EPHX3 gene, is the third defined isozyme in a set of epoxide hydrolaseisozymes, i.e. the epoxide hydrolases. This set includes the Microsomal epoxide hydrolase ; the epoxide hydrolase 2 ; and the far less well defined enzymatically, epoxide hydrolase 4. All four enzyme contain an Alpha/beta hydrolase fold suggesting that they have Hydrolysis activity. EH1, EH2, and EH3 have been shown to have such activity in that they add water to epoxides of unsaturated fatty acids to form vicinal cis products; the activity of EH4 has not been reported. The former three EH's differ in subcellular location, tissue expression patterns, substrate preferences, and thereby functions. These functions include limiting the biologically actions of certain fatty acid epoxides, increasing the toxicity of other fatty acid epoxides, and contributing to the metabolism of drugs and other xenobiotics.
History
EH3 was first named ABHD9 owing to its possession of a particular Protein domain, the Alpha/beta hydrolase fold or α/β hydrolase fold domain. This domain is found in more than 30 other human hydrolytic enzymes including the four epoxide hydrolases. The gene for EH3 was discovered on chromosome locus 19p13.13 in sequencing the human.genome Based on its amino acid sequence, it was projected to encode a protein with an α/β hydrolase fold domain; the encoded protein was therefore dubbed ABHD9. Some 10 years later, ABHD9 was defined to possess the ability to hydrolyze certain fatty acid epoxides.
Expression
Similar to mEH but unlike sEH, EH3 is membrane-bound enzyme. Based on the expression of its mRNA in mouse tissue, EH3 has a very different distribution than mEH or sEH: EH3 expression is high in skin, lung, tongue, esophagus, and stomach; intermediate in pancreas and eye, visceral fat, lymph nodes, spleen, aortic arch, and heart; low in liver, kidney, testis, ovary intestine, and brain; and very low in skeletal muscle. Its expression in human tissues has not yet been reported.
Activity and function
ABHD9 first drew attention is studies that validated that its gene, EPHX3, was hypermethylated on CpG sites in its Promoter in human prostate cancer tissues, particularly in the tissues of more advanced or, base on morphological criteria, more aggressive diseases. This allows that the gene silencing of EPHX3 due to promoter hypermethylation may contribute to the onset and/or progression of prostate cancer. Similar CpG site hypermethylations in the promoter of EPHX3 have been validated for colorectaladenocarcinomas. As similar promoter methylation pattern, although not yet validated, was also found in human malignant melanoma tissues and human gastric cancer cell lines. These studies allow but certainly do not prove that the silencing of EPHX is involved in the development and/or progression of certain cancers in humans. More recently, ABHD9 was characterized as possessing epoxy hydrolase activity for metabolizing epoxyeicosatrienoic acids and epoxides of linoleic acid as follows:
In this particular reaction, the enzyme inactivates the EET and thereby may function to limit the biological activity of this as well as the other EETs upon which it acts in, for example, regulating blood pressure
to a diol, however, the enzyme increases its toxicity in, for example, contributing to acute respiratory distress syndromes. The enzyme thereby may function to limit the cell signaling activity of the EETs yet contribute to the toxic actions of linoleic acid epoxides. While mEH and to a lesser extent sEH metabolize drugs, foreign toxic chemicals, and certain endogenous compounds that are not simple fatty acids, the activity of EH3 on such substrates, while likely, has not yet been reported.
